We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ESC 2024 - In the SLICE-CEA CardioLink-8 study, evolocumab reduced lipid-rich necrotic core volume in patients with severe, asymptomatic carotic artery stenosis compared with placebo. “It suggests that intensive lipid lowering with evolocumab can stablize vulnerable plaques”, says C. David Mazer.
This video was recorded during the ESC Congress 2024 in London, UK.
C. David Mazer is a professor in the Department of Anesthesia and Physiology at the University of Toronto in Toronto, ON, Canada.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of SLICE-CEA CardioLink-8
Release date: 11 September 2024
ESC 2024 - In the SLICE-CEA CardioLink-8 study, evolocumab reduced lipid-rich necrotic core volume in patients with severe, asymptomatic carotic artery stenosis compared with placebo. “It suggests that intensive lipid lowering with evolocumab can stablize vulnerable plaques”, says C. David Mazer.
This video was recorded during the ESC Congress 2024 in London, UK.
C. David Mazer is a professor in the Department of Anesthesia and Physiology at the University of Toronto in Toronto, ON, Canada.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of SLICE-CEA CardioLink-8
Release date: 11 September 2024
Stay current with the best on medical education
